People · Operator
Named in public records as an officer, director or promoter · active 2013–2023 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lycia Therapeutics, Inc. | — | Biotechnology | Series D+ | $202.0M | $1.2B | 2021 |
| Audentes Therapeutics, Inc. | — | Biotechnology | Series C | $107.5M | $2.7B | 2014 |
| Santa Ana Bio, Inc. | — | Biotechnology | Series B | $63.3M | $150.6M | 2021 |
| Kanyos Bio, Inc. | — | Biotechnology | Series A | $16.4M | $376.0M | 2015 |
| Inception IBD, Inc. | — | Pharmaceuticals | Series A | $6.9M | $214.3M | 2015 |
| Jengu Therapeutics, Inc. | — | Biotechnology | Series A | $5.0M | $164.9M | 2020 |
| Euro Ventures 4, Inc. | — | Other | Pre-Seed | $1.0M | $23.1M | 2013 |
Thomas Woiwode at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Woiwode on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clare Ozawa | 3 | 8 |
| Jerel Davis | 2 | 13 |
| Jack Nielsen | 1 | 13 |
| Jonathan Leff | 1 | 11 |
| BRADLEY BOLZON | 1 | 10 |
| Kush Parmar | 1 | 10 |
| Jonathan Silverstein | 1 | 10 |
| Petpiboon Prasit | 1 | 7 |
| William Rieflin | 1 | 4 |
| Laurent Fischer | 1 | 4 |
| Thomas Schuetz | 1 | 4 |
| Florent Gros | 1 | 4 |
| Jeremy Caldwell | 1 | 4 |
| Ming Fang | 1 | 4 |
| Aetna Wun Trombley | 1 | 3 |
| TIM ANDERSON | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| Jeffrey Hubbell | 1 | 2 |
| Brad Bolzon | 1 | 2 |
| Gianni Gromo | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.